Court Decision In Patent Battle Threatens PCSK9 Drug

—-One analyst thinks the decision might take Praluent off the market. A jury’s decision last week in a patent case might possibly lead to the removal of one of the new PCSK9 inhibitor cholesterol lowering drugs from the US market, according to a Wall Street analyst who has been closely following the case. Amgen, which...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Amgen Patent PCSK9 Praluent Regeneron Repatha Sanofi Source Type: blogs